SRSF2 and leukemia: A recent investigation into the prognostic significance of SRSF2 in 187 patients with PMF identified significantly lower median overall survival in patients harboring SRSF2 mutations (24 months) compared with SRSF2 wildtype (65 months); 2-year leukemia risk was also higher with mutated SRSF2 (30 vs. 8%) [47].